GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocumension Therapeutics (HKSE:01477) » Definitions » Other Net Income (Loss)

Ocumension Therapeutics (HKSE:01477) Other Net Income (Loss) : HK$-0.0 Mil (TTM As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Ocumension Therapeutics Other Net Income (Loss)?

Ocumension Therapeutics's Other Net Income (Loss) for the six months ended in Dec. 2024 was HK$0.0 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-0.0 Mil.

Ocumension Therapeutics's quarterly Other Net Income (Loss) declined from Dec. 2023 (HK$0.0 Mil) to Jun. 2024 (HK$-0.0 Mil) but then increased from Jun. 2024 (HK$-0.0 Mil) to Dec. 2024 (HK$0.0 Mil).

Ocumension Therapeutics's annual Other Net Income (Loss) stayed the same from Dec. 2022 (HK$0.0 Mil) to Dec. 2023 (HK$0.0 Mil) but then increased from Dec. 2023 (HK$0.0 Mil) to Dec. 2024 (HK$0.0 Mil).

Ocumension Therapeutics Other Net Income (Loss) Historical Data

The historical data trend for Ocumension Therapeutics's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocumension Therapeutics Other Net Income (Loss) Chart

Ocumension Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Net Income (Loss)
Get a 7-Day Free Trial - - - - -

Ocumension Therapeutics Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Other Net Income (Loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Ocumension Therapeutics Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ocumension Therapeutics Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Ocumension Therapeutics's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocumension Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocumension Therapeutics (HKSE:01477) » Definitions » Other Net Income (Loss)
Comparable Companies
HKSE:02256 HKSE:02315 HKSE:01672 HKSE:06955 HKSE:02616 HKSE:02142 HKSE:06660 HKSE:02157 HKSE:02105 HKSE:02480 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
5DG:Germany
Address
No. 1858 Yinzhongnan Road, Guoxiang Subdistrict, Wuzhong District, Suzhou, Jiangsu, CHN
Website
https://www.ocumension.com
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
Executives
Liu Ye 2101 Beneficial owner
6 Dimensions Capital, L.p. 2101 Beneficial owner
Zhang Qiping 2201 Interest of corporation controlled by you
Su Zhou Fu Yan Chuang Ye Tou Zi Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
6 Dimensions Capital Gp, Llc 2201 Interest of corporation controlled by you
Su Zhou Tong He Er Qi Chuang Ye Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Su Zhou Yun Zhang Tou Zi Zi Xun You Xian Gong Si 2201 Interest of corporation controlled by you
Boyu Capital Fund Iv, L.p. 2201 Interest of corporation controlled by you
Boyu Capital Group Holdings Ltd 2201 Interest of corporation controlled by you
Boyu Capital General Partner Iv, Ltd 2201 Interest of corporation controlled by you
Summer Iris Limited 2101 Beneficial owner
Alcon Pharmaceuticals Ltd 2101 Beneficial owner
Alcon Inc. 2201 Interest of corporation controlled by you
Temasek Holdings (private) Limited 2201 Interest of corporation controlled by you
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you

Ocumension Therapeutics Headlines

No Headlines